Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP 129Xe MRI in Lung Cancer Patients Receiving Radiation Therapy
NCT06909201Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hyperpolarized xenon gas in lung cancer (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Mar 2026; status: recruiting.
02
Drugs
hyperpolarized xenon gas
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06909201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909201.